IL1B and cardiovascular disorder: In addition to the anticipated results in reducing cardiovascular diseases, the CANTOS trial delivered an unexpected finding: the overall mortality rate remained unchanged, despite the inhibition of IL-1β leading to a weakened innate immune system.